Join
Live feed
·
PRReleasevia Quantisnow
Ocugen Inc. logo

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

ByQuantisnow·Wall Street's wire, on your screen.
OCGN· Ocugen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OCGN (Ocugen Inc.) and more on Quantisnow.